Velo3d, Inc. current report, 31 January 2024

Full document

Velo3D, Inc. Form 8-K Summary

Business Context and Reporting Period

Velo3D, Inc. filed a Form 8-K dated January 31, 2024, regarding an amendment to its equity sales arrangement with Needham & Company, LLC. The Sales Agreement was originally entered into on February 6, 2023, under which Needham may sell Velo3D common stock from time to time through an at-the-market offering.

Financing and Key Metrics

  • The original prospectus supplement authorized up to $40.0 million of common stock sales.
  • As of the filing date, Velo3D had sold shares for aggregate gross proceeds of $24,636,166.03 under the Sales Agreement.
  • The amendment increased the aggregate amount of shares available for sale under the arrangement to $75.0 million.
  • The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or share-count information.

Material Changes and Outlook

The material change is the increase in the maximum offering amount from $40.0 million to $75.0 million. The filing does not provide financial guidance, operating outlook, management commentary, or details regarding the intended use of proceeds.

Risks, Contingencies, and Unusual Items

  • The offering may result in additional common-stock issuance and dilution to existing stockholders.
  • Actual proceeds will depend on the timing, volume, and market price of future sales; the filing does not state that the full $75.0 million will be raised.
  • The offering is conducted under Velo3D’s effective Form S-3 shelf registration statement and related prospectus supplement.
  • Fenwick & West LLP provided a legal opinion regarding the shares available for sale.

Investor Verification Checklist

  • Verify the number of shares sold and net proceeds after commissions and expenses.
  • Review subsequent filings for additional sales, remaining capacity, and potential dilution.
  • Confirm how the proceeds are used and assess Velo3D’s current liquidity and financing needs.
  • Review the Form S-3, prospectus supplement, amendment, Sales Agreement, and legal opinion for offering terms and associated risks.